Figure 6.

Kinesin-derived angiogenesis inhibitor (KAI) inhibits angiogenesis and tumor growth in vivo. A: Study of human lung carcinoma H460 xenograft in mice with severe combined immunodeficiency. Mice were treated with KAI (10 mg/kg) or phosphate-buffered saline (PBS), i.v. via tail vein, three times per week, and tumor size is shown in the graph. B and C: Number of vessels in tumor in PBS-treated control and peptide-treated tumor. Representative immunohistochemistry of VEGFR2 and von Willebrand factor (vWF) are shown to visualize blood vessels. D: Apoptotic cells visualized with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay in tumor tissue treated with PBS vehicle or KAI. Data are expressed as means ± SEM (A, B, and D). n = 8 in each group. ^∗P < 0.05, ^∗∗P < 0.01 (t-test). Scale bars = 50 μm (C and D).